News Releases

Date Title and Summary
Toggle Summary electroCore Provides Business Update and Select Financial Guidance
Full year 2020 revenue expected at the upper end of previously announced guidance range of $3.3M - $3.5M ; greater than 40% growth over full year 2019 revenue of $2.4M Net cash used for the fourth quarter 2020 of $3.7 million , compares favorably to previously announced guidance of $4M December 31,
Toggle Summary electroCore, Inc. Announces Agreement with Pro Medical Baltic to be Exclusive Distributor for gammaCore Sapphire™ in Eastern Europe
ROCKAWAY, N.J. , Dec. 21, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc.  (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that it has entered into an agreement with Pro Medical Baltic UAB (“PMB”), whereby PMB will serve as the exclusive distributor of gammaCore
Toggle Summary electroCore Announces Positive Top-Line Results from PREMIUM II Migraine Prevention Study
BASKING RIDGE, N.J. , Dec. 08, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced today top-line results from its GM-US-10 ( PREMIUM II ) study. Despite the early termination of the study in April 2020 due to the COVID-19
Toggle Summary electroCore to Present at the 13th Annual LD Micro Main Event Conference
BASKING RIDGE, N.J. , Dec. 07, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced today that management is scheduled to present at the 13 th Annual LD Micro Main Event Conference . Presentation details: Date: Monday, December 14,
Toggle Summary electroCore Announces Selection of gammaCore for National Institute on Drug Abuse (NIDA)-Sponsored Study in Opioid Use Disorders
BASKING RIDGE, N.J. , Dec. 01, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced today that its gammaCore non-invasive vagus nerve stimulator (nVNS) has been selected for evaluation in a randomized controlled study for the
Toggle Summary electroCore Announces Third Quarter Financial Results
R evenue growth of 44 % over the second quarter of 2020 and 58 % over the third quarter of 2019 R eturn to sequential revenue   growth across all channels Further strengthened balance sheet Reduced quarterly cash burn Company to host conference call and webcast today, November 12 , 2020 at 4:30 pm
Toggle Summary electroCore to Participate in Upcoming Virtual Investor Conferences
BASKING RIDGE, N.J. , Nov. 12, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced today that Dan Goldberger , Chief Executive Officer, and Brian Posner , Chief Financial Officer, will participate in two upcoming investor
Toggle Summary electroCore to Announce Third Quarter Ended September 30, 2020 Financial Results on Thursday, November 12
Conference Call to be Held at 4:30pm Eastern Time BASKING RIDGE, N.J. , Nov. 05, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced that it will report financial results for the third quarter ended September 30, 2020 after the
Toggle Summary electroCore, Inc. Appoints Business Development Leader and US Navy Veteran Sylvester Steele as VP and General Manager of Government Channels Business Unit
Newly created position to focus on driving growth within the Veterans Administration, Department of Defense and other government channels BASKING RIDGE, N.J. , Oct. 21, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced the
Toggle Summary electroCore Provides Business Update and Select Financial Guidance
Third quarter 2020 Revenue expected to exceed $1 million , representing an increase of greater than 35% sequentially and greater than 50% over Q3 2019 Operating cash burn for the third quarter 2020 of approximately $4.1 million BASKING RIDGE, N.J. , Oct.